Anavex Life Sciences Corp (AVXL)

[falconer66a]

Don’t want to “pump.”

Hey falcon can you please share your spreadsheet. Thanks

Thanks for the invitation. The numbers are so big and powerful, when considering how many will be helped with blarcamesine, and how owners of an AVXL equity position will be financially rewarded, I’d therefore really like to let readers see and scrutinize the data themselves.

But, I won’t, and can’t share the spreadsheet.

First, mechanically, I don’t know how to post an Excel spreadsheet file on this message board, to be downloaded by readers. Not sure it can be done.

But even if I could post it, I’d refrain. For some, this would be regarded (already the case, I’m sure) as unsubstantiated and overly optimistic “pumping.” “Look at these numbers! Ain’t Anavex great? Better get your AVXLs at tomorrow’s opening.” Stuff just too good to be true, it would seem to many.

In fact, if a reader isn’t able to plug into his or her own spreadsheet, on one’s own computer, the data I presented (or the data they’d have to look up), and also be unable to usefully connect the cells with the proper controlling arithmetic functions (when to add, multiply, divide, etc.), to see the final big read-outs, the data points on my provided spreadsheet would not be well understood. That could lead to some risky or poorly understood AVXL buys. As pointed out by many here, investing in tiny start-up biotechs is “risky.”

I don’t recommend that anyone decide to take an AVXL equity position, of any size, based on or prompted by the big potential investment reward numbers that anyone’s spreadsheet offers. Instead, decide if the blarcamesine data and information that I and a number of others have presented, along with information on the company website, supports an AVXL position.

In the end, it’s solely a question of the to-be-confirmed quality of the Anavex science. The on-going clinical trials, when they end, will validate the numbers on my, or anyone else’s Anavex spreadsheet.

But, yes, lots and lots of zeros; after some big integers, not after mere decimal points — especially in the cells with the $ symbol as a prefix.

(Remember back in the eighth grade, in math class, the “story problems?” That’s what we have here: how many people will be treated with blarcamesine, at what daily cost, yielding to Anavex Life Sciences Corp how many dollars a year, with what fraction of those revenues ending up getting distributed to Anavex shareholders as dividends? Straight arithmetic; no algebra at all.)